SyntheX (Drug Discovery) Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
Series A
- Investors
-
14
SyntheX (Drug Discovery) General Information
Description
Developer of a proprietary drug discovery platform designed to find protein interaction disruptors, bridgers, and molecular glue degraders. The company utilizes genetically engineered circuits, technologies, and proprietary DNA-encoded peptide and macrocycle libraries that rely on intracellular drug selection as opposed to in vitro screening, enabling healthcare institutions to serve human health for the treatment of cancer and rare diseases.
Contact Information
Website
synthexlabs.comCorporate Office
- 455 Mission Bay Boulevard South
- Suite 145
- San Francisco, CA 94158
- United States
Corporate Office
- 455 Mission Bay Boulevard South
- Suite 145
- San Francisco, CA 94158
- United States
SyntheX (Drug Discovery) Timeline
SyntheX (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series A) | 23-May-2025 | Completed | Pre-Clinical Trials | |||
| 7. Accelerator/Incubator | 10-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 6. Seed Round | 10-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 5. Debt - PPP | 27-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 28-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 01-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 27-Apr-2017 | $6.15M | $6.4M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 01-Mar-2016 | $250K | $250K | Completed | Product In Beta Test |
SyntheX (Drug Discovery) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
SyntheX (Drug Discovery) Comparisons
Industry
Financing
Details
SyntheX (Drug Discovery) Competitors (10)
One of SyntheX (Drug Discovery)’s 10 competitors is PhoreMost, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PhoreMost | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Proxygen | Venture Capital-Backed | Vienna, Austria | ||||
| Cullgen | Formerly VC-backed | San Diego, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA |
SyntheX (Drug Discovery) Patents
SyntheX (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020275425-A1 | Selective degradation of proteins | Active | 15-May-2019 | ||
| AU-2020275425-B2 | Selective degradation of proteins | Active | 15-May-2019 | ||
| AU-2024219968-A1 | Selective degradation of proteins | Pending | 15-May-2019 | ||
| EP-3969592-A4 | Selective degradation of proteins | Pending | 15-May-2019 | ||
| JP-2024019600-A | Selective degradation of proteins | Pending | 15-May-2019 | C40B40/02 |
SyntheX (Drug Discovery) Signals
SyntheX (Drug Discovery) Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Merck Digital Sciences Studio | Accelerator/Incubator | Minority | ||
| The Column Group | Venture Capital | Minority | ||
| Endless Frontier Labs | Accelerator/Incubator | Minority | ||
| OMX Ventures | Venture Capital | Minority | ||
| MBC BioLabs | Accelerator/Incubator | Minority |
SyntheX (Drug Discovery) FAQs
-
When was SyntheX (Drug Discovery) founded?
SyntheX (Drug Discovery) was founded in 2016.
-
Where is SyntheX (Drug Discovery) headquartered?
SyntheX (Drug Discovery) is headquartered in San Francisco, CA.
-
What is the size of SyntheX (Drug Discovery)?
SyntheX (Drug Discovery) has 40 total employees.
-
What industry is SyntheX (Drug Discovery) in?
SyntheX (Drug Discovery)’s primary industry is Drug Discovery.
-
Is SyntheX (Drug Discovery) a private or public company?
SyntheX (Drug Discovery) is a Private company.
-
What is SyntheX (Drug Discovery)’s current revenue?
The current revenue for SyntheX (Drug Discovery) is .
-
How much funding has SyntheX (Drug Discovery) raised over time?
SyntheX (Drug Discovery) has raised $11.6M.
-
Who are SyntheX (Drug Discovery)’s investors?
Merck Digital Sciences Studio, The Column Group, Endless Frontier Labs, OMX Ventures, and MBC BioLabs are 5 of 14 investors who have invested in SyntheX (Drug Discovery).
-
Who are SyntheX (Drug Discovery)’s competitors?
PhoreMost, Proxygen, Cullgen, Arvinas, and Vividion Therapeutics are some of the 10 competitors of SyntheX (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process